-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Denosumab (trade name: Angarve) is a RANKL inhibitor that inhibits the activity of osteoclasts.
It is approved for the treatment of glucocorticoid (GC)-induced osteoporosis and the prevention of tumor bone metastasis
.
This study evaluated the changes in bone turnover and bone mineral density (BMD) in subjects with rheumatoid arthritis (RA) using GC after denosumab was stopped for 12 months
Denosumab (trade name: Angarve) is a RANKL inhibitor that inhibits the activity of osteoclasts.
Randomized, double-blind, placebo-controlled Phase 2 study ( NCT00095498 )
In this post-hoc analysis of subjects who received GC treatment at baseline (N = 82), the CTX and P1NP of the two denosumab groups were significantly lower than the baseline
.
After denosumab was discontinued, CTX returned to baseline levels, and there was no significant difference from placebo at 6 and 12 months after discontinuation
The CTX and P1NP of the two denosumab groups were significantly lower than baseline
Summarize:
Summarize:In an analysis of short-term use of denosumab in subjects with rheumatoid arthritis receiving glucocorticoids , it was found that the withdrawal of denosumab gradually increased bone turnover, and the bone mineral density of the lumbar spine and total hip returned to baseline levels .
In an analysis of short-term use of denosumab in subjects with rheumatoid arthritis receiving glucocorticoids , it was found that the withdrawal of denosumab gradually increased bone turnover, and the bone mineral density of the lumbar spine and total hip returned to baseline levels .Source: Source:
Saag KG, McDermott MT, Adachi J, Lems W, Lane NE, Geusens P, Kees Stad R, Chen L, Huang S, Dore R, Cohen S.
The Effect of Discontinuing Denosumab in Patients With Rheumatoid Arthritis Treated With Glucocorticoids.
Saag KG, McDermott MT, Adachi J, Lems W, Lane NE, Geusens P, Kees Stad R, Chen L, Huang S, Dore R, Cohen S.
The Effect of Discontinuing Denosumab in Patients With Rheumatoid Arthritis Treated With Glucocorticoids.
Arthritis Rheumatol .
2021 Sep 17.
doi: 10.
1002/art.
41981.
Epub ahead of print.
PMID: 34535967.
Leave a message here
